Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
44.2M
-
Number of holders
-
56
-
Total 13F shares, excl. options
-
34.5M
-
Shares change
-
+1.92M
-
Total reported value, excl. options
-
$987M
-
Value change
-
+$52.9M
-
Number of buys
-
32
-
Number of sells
-
-23
-
Price
-
$28.63
Significant Holders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) as of Q2 2021
68 filings reported holding PRLD - Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share as of Q2 2021.
Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) has 56 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.5M shares
of 44.2M outstanding shares and own 78.03% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (10.1M shares), ORBIMED ADVISORS LLC (10M shares), FMR LLC (6.55M shares), UBS ASSET MANAGEMENT AMERICAS INC (1.29M shares), VANGUARD GROUP INC (1.13M shares), STATE STREET CORP (1.05M shares), BlackRock Inc. (703K shares), HHLR ADVISORS, LTD. (583K shares), PRICE T ROWE ASSOCIATES INC /MD/ (401K shares), and Logos Global Management LP (400K shares).
This table shows the top 56 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.